Key Highlights
- Theriva Biologics (TOVX) shares rallied 63% following the disclosure of updated VIRAGE Phase 2b trial results
- Combination therapy of VCN-01 with standard chemotherapy demonstrated enhanced overall survival compared to chemotherapy alone in patients with metastatic pancreatic cancer
- Positive outcomes were observed across multiple patient subgroups, including those with liver metastases
- Theriva has secured regulatory alignment with both FDA and EMA for a forthcoming Phase 3 pivotal study
- The biotech company maintains a market capitalization of only $11.7M with shares trading at $0.25, highlighting its early-stage development risk profile
Theriva Biologics unveiled updated findings from its VIRAGE Phase 2b clinical study during the American Association for Cancer Research (AACR) Annual Meeting held in San Diego on April 20, 2026.
Dr. Manuel Hidalgo from NYU Langone Health’s Perlmutter Cancer Center presented the poster session.
The clinical study evaluated VCN-01 administered alongside gemcitabine and nab-paclitaxel versus chemotherapy alone in individuals with newly diagnosed metastatic pancreatic cancer.
Findings indicated that participants who received VCN-01 in combination with chemotherapy experienced superior overall survival and progression-free survival compared to those receiving only chemotherapy.
The treatment responses observed in the VCN-01 cohort were characterized as emerging later, demonstrating greater magnitude, and proving more durable — suggesting what the company interprets as an immune-mediated therapeutic mechanism.
The survival advantages remained broadly consistent across various patient subgroups. This includes individuals with liver metastases, a population that typically presents greater treatment challenges.
Participants who received a second administration of VCN-01 appeared to demonstrate even more pronounced benefits, which the company states supports the rationale for prolonged dosing strategies.
Regulatory Alignment Secured for Phase 3 Trial
Theriva announced it has obtained alignment with both the U.S. Food and Drug Administration and the European Medicines Agency regarding the framework for a pivotal Phase 3 clinical trial.
The planned Phase 3 study would assess multiple doses of VCN-01 combined with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer patients.
Additionally, the company indicated plans for a supplementary smaller-scale study to investigate whether more frequent or prolonged VCN-01 administration could further enhance clinical outcomes.
VCN-01 is a systemically delivered oncolytic adenovirus. The therapy is engineered to replicate within tumor cells and degrade tumor stroma, potentially enhancing accessibility for concurrently administered treatments.
To date, the experimental treatment has been administered to 142 patients across various clinical trials spanning multiple cancer indications.
Market Response and Company Overview
TOVX shares surged 63% following the announcement, although the company’s market capitalization stands at merely $11.7 million with the stock priced at $0.25.
This valuation underscores the inherent risks associated with a clinical-stage biotechnology firm operating without revenue and experiencing ongoing capital consumption.
Wall Street Perspective
The latest analyst assessment on TOVX assigns a Buy rating, with a price target set at $1.00. Analyst price targets span from $1 to $4.
One notable complication: Theriva recently failed to convene a Special Meeting of Stockholders due to insufficient quorum. The meeting was intended to approve a warrant exercise proposal. The company intends to reschedule the gathering.
Pancreatic ductal adenocarcinoma accounts for over 90% of all pancreatic malignancies, with 50–60% of patients presenting with distant metastases at the time of initial diagnosis.
The AACR presentation occurred on April 20 between 2:00–5:00 PM PDT at the San Diego Convention Center.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
